TAVR for Aortic Valve Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: transcatheter heart valve.
- Who it may be relevant to
- Registry conditions: Aortic Valve Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Transcatheter Aortic Valve Replacement for Severe Aortic Valve Disease: Multi-center, Real-word Registry
Overview
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
Interventions
- Device transcatheter heart valve
patients with severe aortic valve disease underwent transcatheter heart valve
Primary outcome measures
- all-cause death during follow-up [Time frame: 5 years]
Secondary outcome measures (1)
- cardiac death during follow-up [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Clinical diagnosis of severe aortic stenosis or aortic regurgitation
- Patients undergo transcatheter aortic valve replacement
Exclusion criteria
patients refuse the clinical follow-up
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Nanjing First Hospital — Nanjing
Identifiers
NCT: NCT05439863 · NanjingValve Registry